Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
|Articles|November 1, 2017
- Pharmaceutical Executive-11-01-2017
- Volume 37
- Issue 11
Pharmaceutical Executive, November 2017 Issue (PDF)
Click the title above to open the Pharmaceutical Executive November 2017 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 9 years ago
Pharm Exec's 2018 Pipeline Reportalmost 9 years ago
Taiwan’s Biotech Boomalmost 9 years ago
The Fine Line of Pharma & Patient Group Collaborationalmost 9 years ago
FDA Explores Flexible Drug Marketing Policiesalmost 9 years ago
No Overnight Successesalmost 9 years ago
Aligning Early Advice with Long-Term Planningalmost 9 years ago
Navigating the Untapped NASH Marketalmost 9 years ago
Interpreting UK’s Post-Brexit Life Sciences Strategyalmost 9 years ago
When HIPAA Doesn’t Applyalmost 9 years ago
Country Report: AustriaAdvertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Ilumya for Adults With Active Psoriatic Arthritis
2
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
3
Post-Exposure Prophylaxis Is the Missing Piece: Q&A with Florin Draica
4
Closing the Pediatric Evidence Gap
5